In addition, in some phase II clinical trials of mucosal MM caused by KIT mutations, the CR in the Dasatinib-treatment group, which is also a Kit inhibitor, reached only 18%, a significant decrease compared to Imatinib-treatment [52]. This evidence concerns the gene KIT and Miyoshi myopathy.